What a pharmacotherapeutics on asthama nd it's treatment algorithm with reference to standard books and research papers
Reading File
Finding Sources
Finding Sources
Searching PubMed
asthma pharmacotherapy treatment guidelines
Finding Sources
Searching PubMed
asthma management GINA guidelines inhaled corticosteroids
Reading File
Reading File
Finding Sources
Searching PubMed
asthma stepwise therapy bronchodilator
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
Loading Image
Reading File
The above is a comprehensive, evidence-based overview of asthma pharmacotherapeutics. Here is a quick orientation to the sections:
What's covered:
- Pathophysiology — inflammatory basis (mast cells, eosinophils, T-cells)
- Severity classification — NAEPP 4-tier system (Intermittent → Mild/Moderate/Severe Persistent) with FEV₁ cut-offs
- All drug classes — mechanisms, examples, doses, key warnings (LABA Black Box, montelukast FDA warning, theophylline monitoring)
- ICS dose equivalency table — beclomethasone, budesonide, fluticasone, mometasone (low/medium/high)
- Stepwise algorithm — NAEPP 2020, ages 0–4, 5–11, ≥12 years, with visual diagrams directly from textbooks
- SMART therapy — ICS-formoterol as both maintenance and rescue (Steps 3–4)
- Triple therapy — ICS+LABA+LAMA for severe persistent asthma
- Biologics — omalizumab, mepolizumab, benralizumab, dupilumab for Steps 5–6
- Acute exacerbation management — SABA + ipratropium + systemic steroids + magnesium sulfate
- Special populations — pregnancy, exercise-induced bronchospasm
- PubMed-cited recent evidence for triple therapy and pediatric LABA+ICS
Treatment algorithm in flow chart
Checking Date & Time
Running Command
Running Command
Writing File
You've run out of free credits. Sign up for a free account to continue using Orris.
This is a shared conversation. Sign in to Orris to start your own chat.